456 related articles for article (PubMed ID: 21241063)
1. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
[TBL] [Abstract][Full Text] [Related]
3. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.
Doddareddy MR; Klaasse EC; Shagufta ; Ijzerman AP; Bender A
ChemMedChem; 2010 May; 5(5):716-29. PubMed ID: 20349498
[TBL] [Abstract][Full Text] [Related]
4. A novel structure-based virtual screening model for the hERG channel blockers.
Du L; Li M; You Q; Xia L
Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
[TBL] [Abstract][Full Text] [Related]
5. A composite model for HERG blockade.
Kramer C; Beck B; Kriegl JM; Clark T
ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
[TBL] [Abstract][Full Text] [Related]
6. A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability.
Leong MK
Chem Res Toxicol; 2007 Feb; 20(2):217-26. PubMed ID: 17261034
[TBL] [Abstract][Full Text] [Related]
7. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
8. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
[TBL] [Abstract][Full Text] [Related]
9. hERG classification model based on a combination of support vector machine method and GRIND descriptors.
Li Q; Jørgensen FS; Oprea T; Brunak S; Taboureau O
Mol Pharm; 2008; 5(1):117-27. PubMed ID: 18197627
[TBL] [Abstract][Full Text] [Related]
10. The molecular determinants of R-roscovitine block of hERG channels.
Cernuda B; Fernandes CT; Allam SM; Orzillo M; Suppa G; Chia Chang Z; Athanasopoulos D; Buraei Z
PLoS One; 2019; 14(9):e0217733. PubMed ID: 31479461
[TBL] [Abstract][Full Text] [Related]
11. Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs.
Durdagi S; Subbotina J; Lees-Miller J; Guo J; Duff HJ; Noskov SY
Curr Med Chem; 2010; 17(30):3514-32. PubMed ID: 20738248
[TBL] [Abstract][Full Text] [Related]
12. A binary QSAR model for classification of hERG potassium channel blockers.
Thai KM; Ecker GF
Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
[TBL] [Abstract][Full Text] [Related]
13. Computer simulations of structure-activity relationships for HERG channel blockers.
Boukharta L; Keränen H; Stary-Weinzinger A; Wallin G; de Groot BL; Aqvist J
Biochemistry; 2011 Jul; 50(27):6146-56. PubMed ID: 21657256
[TBL] [Abstract][Full Text] [Related]
14. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques.
Ekins S; Balakin KV; Savchuk N; Ivanenkov Y
J Med Chem; 2006 Aug; 49(17):5059-71. PubMed ID: 16913696
[TBL] [Abstract][Full Text] [Related]
15. First universal pharmacophore model for hERG1 K
Durdagi S; Erol I; Salmas RE; Patterson M; Noskov SY
J Mol Graph Model; 2017 Jun; 74():153-170. PubMed ID: 28499268
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant.
Hosaka Y; Iwata M; Kamiya N; Yamada M; Kinoshita K; Fukunishi Y; Tsujimae K; Hibino H; Aizawa Y; Inanobe A; Nakamura H; Kurachi Y
Channels (Austin); 2007; 1(3):198-208. PubMed ID: 18690032
[TBL] [Abstract][Full Text] [Related]
17. In silico prediction of hERG inhibition.
Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
[TBL] [Abstract][Full Text] [Related]
18. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W
J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718
[TBL] [Abstract][Full Text] [Related]
19. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.
Taboureau O; Jørgensen FS
Comb Chem High Throughput Screen; 2011 Jun; 14(5):375-87. PubMed ID: 21470179
[TBL] [Abstract][Full Text] [Related]
20. A novel hypothesis for the binding mode of HERG channel blockers.
Choe H; Nah KH; Lee SN; Lee HS; Lee HS; Jo SH; Leem CH; Jang YJ
Biochem Biophys Res Commun; 2006 May; 344(1):72-8. PubMed ID: 16616004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]